GLP Watchdog

Hims vs SkinnyRx

Hims has an open FDA warning letter dated September 9, 2025. SkinnyRx has an open FDA warning letter dated February 20, 2026. No price lines up like for like. They share brand-name semaglutide pen, but Hims' $199 covers the medication only, with a separate membership on top.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hims / SkinnyRx

Hims logo

Hims

6.7/10

Featured pick (affiliate partner)

SkinnyRx logo

SkinnyRx

6.3/10

FDA warning letters
Pharmacy
None named in our record
Lowest standing price
$149/moBrand-name semaglutide pill, medication only, membership extra
$248/moBrand-name semaglutide pill
States
All 50 states
47 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Hims
Visit SkinnyRx

SkinnyRx is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Hims pays us nothing. The scores are computed the same way for both and are shown as computed (Hims 6.7, SkinnyRx 6.3). How we are paid

What the record shows

  1. 01

    Hims has an open FDA warning letter dated September 9, 2025. SkinnyRx has an open FDA warning letter dated February 20, 2026.

  2. 02

    SkinnyRx names no compounding pharmacy in our record. Hims sells brand-name medication only.

  3. 03

    No price lines up like for like. They share brand-name semaglutide pen, but Hims' $199 covers the medication only, with a separate membership on top.

  4. 04

    Only SkinnyRx lists a price for compounded semaglutide injection, compounded tirzepatide injection and compounded oral semaglutide.

  5. 05

    Hims covers three states SkinnyRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hims

SkinnyRx

Brand-name semaglutide pen

$199/mo

medication only, membership extra; not compared

$1,400/mo

$16,800 a year

Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

$1,400/mo

$16,800 a year

Brand-name semaglutide pill

$149/mo

medication only, membership extra; not compared

$248/mo

$2,976 a year

Foundayo (orforglipron) pill

$149/mo

medication only, membership extra; not compared

$248/mo

$2,976 a year

Compounded semaglutide injection
Not sold or not priced

$99/mo

first month only; not compared

Compounded tirzepatide injection
Not sold or not priced

$99/mo

first month only; not compared

Compounded oral semaglutide
Not sold or not priced

$149/mo

first month only; not compared

Compounded oral tirzepatide
Not sold or not priced

$199/mo

first month only; not compared

Price includes
Medication
Medication, clinician visits, shipping
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
Monthly membership, auto-renews
None stated; subscriptions auto-renew until canceled at least 5 days before the renewal date
Refunds
First month's membership fee is non-refundable; partial-period refunds are not guaranteed
Full refund before a provider completes the prescription review; no refunds for partially used subscription periods
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Hims: October 17, 2026. SkinnyRx: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hims

6.7/10

The record gives Hims no edge on this pair.

  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
  • Lowest price covers the medication only, with a separate membership on top
Visit Hims

The case for SkinnyRx

6.3/10
Featured pick (affiliate partner)
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which Hims does not price
  • Price includes clinician visits
  • Open FDA warning letter, February 20, 2026
  • Names no compounding pharmacy
Visit SkinnyRx

Scores

Hims 6.7 · SkinnyRx 6.3 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
5.6

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
3.0

Trust & Safety15%

6.0A
vs
B
2.0

Accessibility10%

10.0A
vs
B
9.5

Support10%

3.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Hims vs SkinnyRx: questions

Hims has an open FDA warning letter dated September 9, 2025. SkinnyRx has an open FDA warning letter dated February 20, 2026. Letters are matched to a seller by company, domain and address, never by a similar name.
SkinnyRx names no compounding pharmacy in our record. Hims sells brand-name medication only. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like. They share brand-name semaglutide pen, but Hims' $199 covers the medication only, with a separate membership on top. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
Hims states you can cancel at any time; refunds: first month's membership fee is non-refundable; partial-period refunds are not guaranteed. SkinnyRx states you can cancel at any time; refunds: full refund before a provider completes the prescription review; no refunds for partially used subscription periods.
SkinnyRx is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. Hims pays us nothing. The scores are computed the same way for both and are shown as computed (Hims 6.7, SkinnyRx 6.3).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks